Elza Lomaia - Concepedia

Author

Elza Lomaia

Federal Almazov North-West Medical Research Centre

Also Known As

E G LOMAIA, E Lomaia, E. G. Lomaia, E. Lomaia, Elza G. Lomaia, Elza Galaktionovna Lomaia, Elza Lomaia, L. L. Girshova

127

Publications

549

Citations

H-Index

Concepts

All Affiliations

Federal Almazov North-West Medical Research Centre National Medical Research Center for Hematology The University of Texas MD Anderson Cancer Center Imperial College London Russian Research Institute of Hematology and Transfusiology

About

Elza Lomaia is an author at Federal Almazov North-West Medical Research Centre specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	221
2	Health Sciences	3	3	187
3	Molecular Medicine	3	3	160
4	Pathology	2	2	61
5	Immunology	1	1	14

Elza Lomaia

Publications

421

Citations

H-Index

Page 1

	Year	Citations
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Leukemia Mixed-phenotype Acute LeukemiaAsciminib Vs BosutinibPharmacotherapyLonger-term Follow-upMyeloid Neoplasia	2023	126
First‐line treatment selection and early monitoring patterns in chronic phase‐chronic myeloid leukemia in routine clinical practice: SIMPLICITY Stuart L. Goldberg, Jörge E. Cortes, Carlo Gambacorti‐Passerini, American Journal of Hematology	2017	39
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study Vikas Gupta, Martin Grießhammer, Bruno Martino, Leukemia & lymphoma/Leukemia and lymphoma PrognosisPathologyPharmacotherapyLogistic AnalysisMyeloid Neoplasia	2020	33
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin Michael Lauseker, Katharina Bachl, Anna Turkina, American Journal of Hematology Hematological MalignancyChronic Myeloid LeukemiaHealth SciencesMedicineMixed-phenotype Acute Leukemia	2019	28
Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs Andreas Hochhaus, Carla Boquimpani, Delphine Réa, Blood	2020	26
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib Elias Jabbour, Vivian G. Oehler, Paul Koller, JAMA Oncology	2024	21
Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses. Jörge E. Cortes, Elza Lomaia, Anna Turkina, Journal of Clinical Oncology Vascular DiseaseOcular DiseaseCardiovascular PharmacologyPharmacotherapyDose-ranging Study	2020	20
PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I Anna Turkina, Olga Vinogradova, Elza Lomaia, Blood	2019	18
Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks Michael J. Mauro, Yosuke Minami, Delphine Réa, Blood	2021	18
Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia Elza Lomaia, Andrey Zaritskey, Vasily Shuvaev, Blood	2015	15

Page 1